Initial treatment with fixed-dose combination rosiglitazone/glimepiride in patients with previously untreated type 2 diabetes.

@article{Chou2008InitialTW,
  title={Initial treatment with fixed-dose combination rosiglitazone/glimepiride in patients with previously untreated type 2 diabetes.},
  author={Hubert S. Chou and Jerry P. Palmer and Alexis R Jones and Brian R. Waterhouse and C Ferreira-Cornwell and J{\"o}rg Krebs and Barry J. Goldstein},
  journal={Diabetes, obesity & metabolism},
  year={2008},
  volume={10 8},
  pages={
          626-37
        }
}
AIM This study assessed the efficacy and safety of two different dosing regimens of fixed-dose combination (FDC) rosiglitazone (RSG) plus glimepiride (GLIM) compared with RSG or GLIM monotherapy in drug-naive subjects with type 2 diabetes mellitus (T2DM). METHODS Drug-naive subjects (n = 901) were enrolled into this 28-week, double-blind, parallel-group study if their glycosylated haemoglobin A(1c) (HbA(1c)) was >7.5% but <or=12%. Subjects were randomized to receive either GLIM [4 mg once… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 13 CITATIONS

Similar Papers

Loading similar papers…